Evidence map›Paper›PMID 41169500›Full record

ReviewiScience2025

Current advances in diabetic neuropathy: Proteins as therapeutic targets.

Gurjeet Kaur, Salaha Osman Ali, Alberto Santos, Tina Okdahl, Anne-Marie Wegeberg, Tarunveer S Ahluwalia, Christian Stevns Hansen, David Wishart, Nicolai J Wewer Albrechtsen, Birgitte Brock and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gurjeet KaurSteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.
Salaha Osman AliInstitute of Pharmaceutical Science, School of Life Science & Medicine, King's College London, London, UK.
Alberto SantosNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Tina OkdahlMech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Anne-Marie WegebergMech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Tarunveer S AhluwaliaSteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.
Christian Stevns HansenSteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.
David WishartUniversity of Alberta, Edmonton, AB, Canada.
Nicolai J Wewer AlbrechtsenNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.
Birgitte BrockSteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.
Troels Staehelin JensenDanish Pain Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Peter RossingSteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.
Christina BrockMech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Cristina Legido-QuigleySteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.
Karolina SulekSteno Diabetes Center Copenhagen, Clinical Research, Translational Type 1 Diabetes, Translational Medicine, Herlev, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic neuropathy is a debilitating complication of diabetes characterized by nerve damage that may lead to numbness, foot ulcers, and amputations, and is a major cause of morbidity and mortality in people with diabetes. There are no treatments available for diabetic neuropathy aside from pain management. Recent advances in protein research have identified potential targets associated with the disease development and progression. This review explores the latest studies identifying proteins as possible drug targets in diabetic neuropathy and their role in relevant processes such as polyol metabolism, oxidative stress, and cytokine regulation. Additionally, we provide a comprehensive view of current developments and discoveries at single cell and spatial resolution that have revealed deregulated protein profiles in the dorsal root ganglia, sciatic nerve, trigeminal ganglion, or Schwann cells. Finally, we discuss the benefits of proteomics technologies to identify proteins and associated signaling pathways to better understand the source of diabetic neuropathy.

Indexed as

EndocrinologyHuman metabolismPathology

Identifiers

PMID41169500
PMCPMC12570351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.